Early Access Agreement Sample Contracts
AMENDED AND RESTATED EARLY ACCESS AGREEMENTEarly Access Agreement • May 8th, 2017 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 20th day of May, 2016, (“Effective Date”) by and between
EARLY ACCESS AGREEMENTEarly Access Agreement • June 19th, 2015 • Celsion CORP • Pharmaceutical preparations
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 13th day of January 2015 (“Effective Date”) by and between
AMENDMENT NO. 2 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharna, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 28 of June 2017 (the “Amendment No. 2 Effective Date”).
DOMAIN MONEY, INC. EARLY ACCESS AGREEMENTEarly Access Agreement • May 27th, 2023
Set forth below are very important terms and conditions related to your participation in Domain Money’s Early Access Test Program (“Early Access”).
EARLY ACCESS AGREEMENTEarly Access Agreement • August 12th, 2015 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 3rd day of August, 2015, (“Effective Date”) by and between
Early Access AgreementEarly Access Agreement • February 6th, 2019
These terms (the “Early Access Agreement”) supplement the Anaplan SaaS Subscription Agreement, or other agreement governing Client’s use of the Anaplan hosted Service, (the “Client Agreement”) by and between Anaplan and your organization (as named in the Client Agreement). These terms, in addition to the Client Agreement, govern the use of the Early Access Technology, identified below, made available by Anaplan, and are effective immediately when you click accept or first access or use the Early Access Technology.
Early Access AgreementEarly Access Agreement • March 12th, 2021 • England and Wales
This agreement (hereinafter ‘Agreement’) define terms of early access to and use of the Minter Platform and Minter Network.
AMENDMENT NO. 1 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This First Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of December 13, 2106 (the “Amendment No. 1 Effective Date”).
Seldon Technologies Limited – Early Access Agreement Defined TermsEarly Access Agreement • January 21st, 2020 • England and Wales
Seldon Seldon Technologies Limited incorporated and registered in England and Wales with company number 09188032 whose registered office is at Stapleton House 2nd Floor, 110 Clifton Street, London, EC2A 4HT E-mail contact details: legal@seldon.io Participant The company to which the Seldon Product is delivered. Services Risk-free evaluation of Seldon Deploy ML Model deployment platform - two months no-fee access. Understand how the technology can benefit your team. Influence the development of our product, and ensure it is best suited to your organisation. Learn cutting-edge ML ops techniques from the team building the next generation of tools. Product Seldon Deploy - a modern UI for production machine learning model management. Features Description • Deploy pre-packaged model servers • Launch canary using pre-packaged model server • Basic GitOps support with automated commits to GitHub • Visual overview of Seldon Deployments Model Monitoring • Standard HTTP requests
AMENDMENT NO. 3 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This third Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 14 February 2018 (the “Amendment No. 3 Effective Date”).
EARLY ACCESS AGREEMENTEarly Access Agreement • February 14th, 2014 • DanDrit Biotech USA, Inc. • Blank checks
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 20th day of December 2013 (“Effective Date”) by and between
EARLY ACCESS AGREEMENT FOR SURVEY PURPOSESEarly Access Agreement • October 18th, 2018
AMENDMENT NO. 4 TO EARLY ACCESS AGREEMENTEarly Access Agreement • March 30th, 2018 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This fourth Amendment to the Early Access Agreement (the “Agreement”) dated 20th May 2016, by and between Hemispherx Biopharma, Inc. (“HEMISPHERX”), and Impatients N.V. (“IMPATIENTS”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of 26 March 2018 (the “Amendment No. 4 Effective Date”).
EARLY ACCESS AGREEMENTEarly Access Agreement • July 27th, 2015
Sellers, and Purchasers, concerning property legally described as set forth in the below referenced Purchase and Sale agreement and commonly known as:
AGREEMENT CONCERNING EARLY ACCESS TO PROPERTYEarly Access Agreement • October 13th, 2015